DECIPHERA PHARMACEUT

DCPH
Delayed Quote. Delayed  - 12/03 04:00:00 pm
8USD -2.79%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.

Number of employees : 350 people.
Sales per Business
20192020
Kinase Switch Control Inhibitor Platform25.00100%42.09100%
USD in Million
Sales per region
2020
United States38.0090.3%
Global2.606.2%
Non-United States1.503.6%
USD in Million
Managers
Name Title
Steven L. Hoerter President, Chief Executive Officer & Director
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP
James A. Bristol Chairman
Daniel L. Flynn Chief Scientific Officer & Executive VP
Stephen B. Ruddy Chief Technical Officer
Matthew L. Sherman Chief Medical Officer & Executive Vice President
Patricia L. Allen Independent Director
Edward J. Benz Independent Director
John R. Martin Independent Director
Dennis L. Walsh Independent Director
Shareholders
Name Equities %
Brightstar Associates LLC 16,572,370 28.6%
Deerfield Management Company LP 4,203,900 7.24%
Redmile Group LLC 4,031,521 6.95%
The Vanguard Group, Inc. 3,826,157 6.59%
Franklin Advisers, Inc. 3,184,051 5.49%
OrbiMed Advisors Private Equity 2,183,143 3.76%
SSgA Funds Management, Inc. 1,920,920 3.31%
Logos Global Management LP 1,850,000 3.19%
ArrowMark Colorado Holdings LLC 1,812,710 3.12%
New Leaf Venture Partners LLC 1,209,571 2.08%
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
DECIPHERA PHARMACEUTICALS, INC.-85.98%468
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819
BEIGENE, LTD.36.22%32 284
GENMAB A/S-0.24%24 414
ARGENX SE5.17%14 799
ACCELERON PHARMA INC.39.71%10 932
HUALAN BIOLOGICAL ENGINEERING INC.-32.65%8 140
ASCENDIS PHARMA A/S-15.09%7 692
NEUROCRINE BIOSCIENCES, INC.-15.71%7 559
MIRATI THERAPEUTICS, INC.-39.88%7 308
ARROWHEAD PHARMACEUTICALS, INC.-12.03%7 055
GW PHARMACEUTICALS PLC89.72%6 907
SAREPTA THERAPEUTICS, INC.-53.96%6 836
REMEGEN CO., LTD.5.21%6 281
LEGEND BIOTECH CORPORATION76.99%5 904
BIOCON LIMITED-21.18%5 799
MARAVAI LIFESCIENCES HOLDINGS, INC.50.27%5 541
Brand Portfolio
» More brands of Deciphera Pharmaceuticals, Inc.